MANH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Manhattan Associates Inc (MANH) is not a strong buy for a beginner, long-term investor at this moment. While the company has demonstrated consistent financial growth and maintains a leadership position in supply chain management, the stock's technical indicators are mixed, with bearish moving averages and neutral RSI. Additionally, the recent price target adjustments and conservative guidance suggest limited near-term upside. The options data indicates a lack of strong bullish sentiment, and there are no significant positive catalysts to justify immediate action. Holding off for now is recommended.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 49.554, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 138.595, with key resistance at 145.46 and support at 131.73. Overall, the technical indicators suggest a mixed trend with no clear buy signal.
Strong Q4 2025 financial performance with revenue up 5.7% YoY, net income up 8.2% YoY, and EPS up 11.69% YoY.
Leadership in supply chain management and potential for sustained growth in cloud subscription revenue.
Analyst confidence in long-term growth drivers, with price targets from Truist and DA Davidson at $240.
Conservative FY26 guidance with slower revenue growth expectations (3%-6%).
Recent insider selling by Brown Capital Management, though attributed to investor outflows.
Stock price down 28.4% YoY, reflecting broader market concerns.
Mixed analyst ratings, with Morgan Stanley lowering its price target to $165 and citing potential headwinds.
In Q4 2025, Manhattan Associates reported a 5.7% YoY increase in revenue to $270.39M, an 8.2% YoY increase in net income to $51.95M, and an 11.69% YoY increase in EPS to $0.86. However, gross margin dropped slightly to 54.41%, down 1.41% YoY.
Analysts have mixed views. DA Davidson and Truist maintain Buy ratings with price targets of $240, citing strong Q4 results and long-term growth drivers. However, Morgan Stanley downgraded its price target to $165, citing concerns over slowing RPO growth and renewal headwinds.
